Skip to main content
Home
  • en
  • fr
  • Profile
    • About DEINOVE
    • Board of Directors
    • Executive Committee
  • Science
    • Dark biodiversity
    • New antimicrobials
    • Beyond antimicrobials
  • R&D
    • Innovation engine overview
    • Extracting microbial biodiversity
    • Screening for new activity
    • Active compound characterization
    • Preindustrial production
    • Preclinical development
    • Clinical development
  • Technologies
    • Technology platform overview
    • Biodiversity farming
    • Activity testing
    • Advanced analytics
    • Synthetic biology
    • Data Science
    • Fermentation engineering
    • Bioprocess engineering
  • Pipeline
    • Pipeline overview
    • DNV3837
    • AGIR
    • DASMA
  • Partnering
    • New antimicrobials
    • Beyond antimicrobials
  • Investors
    • Corporate governance
    • DEINOVE Shares
    • Financial Calendar
    • Documentation Center
    • Press releases
    • Investor relations
  • News
    • Press releases
    • Events
  1. Home
  2. News
  3. Press releases

Press releases

11.06.2019

DEINOVE and AVRIL completing the development of a natural feed additive

The tests aimed at validating the dosage required have confirmed a very good efficacy of the ingredient The teams are working to develop a...
05.06.2019

DEINOVE & Dow sign a collaboration agreement for the development of a new cosmetic active ingredient

Dow has selected an extract belonging to the DEINOVE proprietary strains’ bank to launch a new cosmetic active ingredient for skin care...
21.05.2019

Anne ABRIAT-HEMMENDINGER appointed to the Board of Directors of DEINOVE

Her proven experience in the beauty industry, particularly within the L'Oréal Group, will be a key asset in DEINOVE's innovation approach...
20.05.2019

The US Department of Defense and Deinove will present impactful R&D results during the coming ASM 2019

The USAMRIID (United States Army Medical Research Institute of Infectious Diseases) evaluated DNV3681 against Bacillus anthracis that...
16.05.2019

DEINOVE is now ready to start Phase II clinical trial for its antibiotic compound DNV3837

Having reached a sufficient number of clinical centers, Phase II clinical trial testing the antibiotic candidate DNV3837 in Clostridioides[...
13.05.2019

The mechanism of action of Phytoene applied to dermocosmetic now determined and promoted at the NYSCC Suppliers' day

DEINOVE has developed a unique bioproduction process that leads to the first 100% pure Phytoene with an anti-aging action which mechanism...
12.04.2019

DEINOVE invited to present at the 29th congress of the European Society of Clinical Microbiology and Infectious Diseases

Georges GAUDRIAULT, Scientific Director of DEINOVE, will give a talk at the ECCMID, at the ‘Therapeutics pipeline corner’, on this coming...
09.04.2019

Novel antibiotics: DEINOVE signs an agreement with the Institut Pasteur to explore the potential of new targeted strains

The Institut Pasteur will provide a selection of strains for the DEINOVE platform to evaluate their potential antibiotic and antifungal...
28.03.2019

2018 Annual Results: a year of significant progress

Finalization of the acquisition of DNV3837, a promising antibiotic for treating severe gastrointestinal infections caused by Clostridium...
21.03.2019

DEINOVE passes the first milestone of the AGIR program and receives €1.5m from Bpifrance

The robotic platform for extracting and screening antibiotic activities from bacterial strains is now operational for the analysis of...
  • « first
  • ‹ previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • next ›
  • last »

News

  • Press releases
  • Events
  • Careers
  • Contact
  • Legal Info
  • Site map
  • Privacy Policy

Follow us

         

Stay in touch

Subscribe to our newsletter

Contact us

Location

ZAC Euromédecine II, Cap Sigma, 1682 Rue de la Valsière, 34790 Grabels, France

+33 (0)4 48 19 01 00

Home